Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy

Breast

Volumn 23, Issue 4, 2014, Pages 473-481

  Bozovic Spasojevic, Ivana ^a,d   Ameye, Lieveke ^a   Paesmans, Marianne ^a   Larsimont, Denis ^a   Di Leo, Angelo ^b   Dolci, Stella ^a   Piccart, Martine ^a   de Azambuja, Evandro ^a   Loi, Sherene ^a,c  

^a JULES BORDET INSTITUTE   (Belgium)

^b Istituto Toscano Tumori   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

BCL2; Biomarkers; Breast cancer; Expression; Prognosis; TP53

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BELGIUM; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; METHOTREXATE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902548579     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.03.012     Document Type: Article

References (26)

1. Haybittle J.L., Blamey R.W., Elston C.W., et al. Aprognostic index in primary breast cancer. Br J Cancer 1982, 45:361-366.
2. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. JClin Oncol 2001, 19:980-991.
3. Evan G.I., Brown L., Whyte M., et al. Apoptosis and the cell cycle. Curr Opin Cell Biol 1995, 7:825-834.
4. Callagy G.M., Pharoah P.D., Pinder S.E., et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006, 12:2468-2475.
5. Callagy G.M., Webber M.J., Pharoah P.D., et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153.
6. Dawson SJ, Makretsov N, Blows FM, etal. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer;103:668-75.
7. Silvestrini R., Veneroni S., Daidone M.G., et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. JNatl Cancer Inst 1994, 86:499-504.
8. Pharoah P.D., Day N.E., Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999, 80:1968-1973.
9. Di Leo A., Tanner M., Desmedt C., et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 2007, 18:997-1003.
10. Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, etal. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res;14:R70.
11. Mottolese M., Benevolo M., Del Monte G., et al. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. JCancer Res Clin Oncol 2000, 126:722-729.
12. Gerlinger M, Rowan AJ, Horswell S, etal. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med;366:883-92.
13. Lindstrom LS, Karlsson E, Wilking UM, etal. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol;30:2601-8.
14. Piccart M.J., Di Leo A., Beauduin M., et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. JClin Oncol 2001, 19:3103-3110.
15. de Azambuja E., Paesmans M., Beauduin M., et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. JClin Oncol 2009, 27:720-725.
16. Cardoso F., Di Leo A., Larsimont D., et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001, 12:615-620.
17. Cardoso F., Paesmans M., Larsimont D., et al. Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer 2004, 5:364-369.
18. Schemper M., Smith T.L. Anote on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
19. Daidone M.G., Luisi A., Veneroni S., et al. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999, 6:61-68.
20. Sparano J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006, 7:347-350.
21. Silvestrini R., Benini E., Daidone M.G., et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. JNatl Cancer Inst 1993, 85:965-970.
22. Allred D.C., Clark G.M., Elledge R., et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. JNatl Cancer Inst 1993, 85:200-206.
23. Bonnefoi H, Piccart M, Bogaerts J, etal. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol;12:527-39.
24. Gasparini G., Barbareschi M., Doglioni C., et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995, 1:189-198.
25. Elledge R.M., Green S., Howes L., et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. JClin Oncol 1997, 15:1916-1922.
26. Bertheau P., Turpin E., Rickman D.S., et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007, 4:e90.